Search Clinical Trials | Froedtert & MCW

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

220 results

A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma

This is a Phase 1, First-in-Human clinical trial, meaning that it is the first study where TNB-486 will be given to humans. This study is open-label, meaning that everyone on the study will receive study drug, at various doses.
The purpose of the Study is:
• To find the highest dose of the study drug that can be given without causing severe side effects.
• To identify side effects of the study drug at different doses.
• To gather early information about how well the study drug treats lymphoma
• To measure the amount of the study drug in the blood at different timepoints after study drug administration, at different doses.
• To evaluate biomarkers in your blood or other parts of your body. A biomarker is a substance in your blood or other location that may tell us something about your disease, indicate how your disease is progressing, or provide information about how effective a study drug is.

Protocol No

TENEOBIO-TENEOTWO-TNB486-001

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Testing the Addition of an Antibody toStandard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients
With Unresectable Stage III Non-Small Cell Lung Cancer

Protocol No

ECOG-EA5181

Sub Category

Thoracic Cancers

A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer

Protocol No

IIT-AWAN-NIH-DEHART

Sub Category

Head and Neck Cancers

A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

Testing the Combination of Pevonedistat with Chemotherapy for Bile Duct Cancer of the Liver

Protocol No

ECOG-EA2187-ICC

Sub Category

Gastrointestinal Cancers

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL

Protocol No

JUNO-017004-TRANSCEND-CLL

Sub Category

Hematologic/Blood Related Cancers

An open-label, Phase 2a/2b study of KRT-232 in subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV-MF), or Post Essential Thrombocythemia MF (Post ET-MF) who have failed prior treatment with a JAK inhibitor

KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor

Protocol No

KARTOS-KRT-232-101-MF

Sub Category

Hematologic/Blood Related Cancers

A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients with or without Renal Insufficiency

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple

Protocol No

IIT-DHAKAL-VICD-MM

Sub Category

Hematologic/Blood Related Cancers

A Phase 1 Study to Evaluate the Safety of BB2121 in Subjects with High Risk Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

A Study to Evaluate the Safety of bb2121 in Subjects with High Risk NDMM (KarMMa4)

Protocol No

CELGENE-BB2121-MM-004-KARMMA4

Sub Category

Hematologic/Blood Related Cancers

Mindfulness meditation and sleep disturbance in hematopoietic cell transplant patients: inflammatory mechanisms

Mindfulness meditation and sleep disturbance in hematopoietic cell transplant patients

Protocol No

IIT-KNIGHT-SLEEPHCT

Sub Category

Hematologic/Blood Related Cancers

Forty-Seven-5F9009-MDS: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk MDS

Magrolimab + Azacitidine versus Azacitidine + Placebo in Untreated MDS

Protocol No

FORTYSEVEN-5F9009-MDS

Sub Category

Hematologic/Blood Related Cancers

A Phase II Study of Split-Dose R-CHOP in Older Adults with Diffuse Large B-cell Lymphoma

Split-Dose R-CHOP for Older Adults with DLBCL

Protocol No

WON-SHAH-UW18131-SPLIT-RCHOP

Sub Category

Hematologic/Blood Related Cancers

An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas (NAPOLI 3)

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

Protocol No

IPSEN-D-US-60010-001-NAPOLI-3

Sub Category

Gastrointestinal Cancers

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

Protocol No

MERCK-MK-3475-992

Sub Category

Prostate and Urologic Cancers

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.

Protocol No

ECOG-EA2182-DECREASE

Sub Category

Gastrointestinal Cancers

Prospective Multicenter Study to Measure the Impact of MMprofiler on Treatment Intention in Active Multiple Myeloma Patients

PRospective Observational Multiple Myeloma Impact Study

Protocol No

SKYLINE-PROMMIS-MM

Sub Category

Hematologic/Blood Related Cancers

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineer NY-ESO-1 Specified (c259) T Cells, Alone or in combination with other agents, in HLA-A@+ Participants with NY-ESO-1 and/or LAGE -1a Positive Solid Tumors

Study of Genetically Engineered T Cells in NY-ESO-1 +/or LAGE-1a + Solid Tumors

Protocol No

GSK-3377794-208467-SARCOMA

Sub Category

Sarcoma

A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Protocol No

RTOG-1008

Sub Category

Head and Neck Cancers

A Topical Antiseptic Bundle for Decreasing Surgical Site Infection after Head Neck Cancer Surgery: Peri-operative Effects on the Oral Microbiome

Topical Antisepsis in Head and Neck Cancer Surgery

Protocol No

IIT-ZENGA-ANTISEPSIS

Sub Category

Head and Neck Cancers

A Phase I/II Study of TheraT^® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

This study is to investigate the study drug in patients with a specific type of cancer called human papillomavirus 16-positive (HPV 16+) cancers. HPV 16+ cancers include head and neck, cervical, anal, vaginal, vulvar, and penile cancers. The main goal of the study is to determine whether HB-201 and HB-202 are effective in the treatment of human papillomavirus 16 positive (HPV 16+) confirmed cancers.

Protocol No

HOOKIPA-H-200-001

Sub Category

Gynecologic Cancers

Early Phase/Multiple Disease Site Cancers

Head and Neck Cancers

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Protocol No

NRG-GU002

Sub Category

Prostate and Urologic Cancers